The outcome of COVID‐19 in children with chronic lung disease: Systematic review and meta‐analyses
Background Few studies have examined the impact of Coronavirus disease 2019 (COVID‐19) infection on children with chronic lung disease (CLD). Objective To perform a systematic review and meta‐analysis to determine the prevalence, risk factors for contracting COVID‐19, and complications of COVID‐19,...
Gespeichert in:
| Veröffentlicht in: | Pediatric pulmonology 2023-06, Vol.58 (6), p.1784-1797 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1797 |
|---|---|
| container_issue | 6 |
| container_start_page | 1784 |
| container_title | Pediatric pulmonology |
| container_volume | 58 |
| creator | Sallih, Aimi Suhaili Mohd Wee, Mae Wae Zaki, Rafdzah A. Hng, Shih Ying Eg, Kah Peng Nathan, Anna M. Bruyne, Jessie A. |
| description | Background
Few studies have examined the impact of Coronavirus disease 2019 (COVID‐19) infection on children with chronic lung disease (CLD).
Objective
To perform a systematic review and meta‐analysis to determine the prevalence, risk factors for contracting COVID‐19, and complications of COVID‐19, in children with CLD.
Methods
This systematic review was based on articles published between January 1, 2020 and July 25, 2022. Children under 18 years old, with any CLD and infected with COVID‐19 were included.
Results
Ten articles involving children with asthma and four involving children with cystic fibrosis (CF) were included in the analyses. The prevalence of COVID‐19 in children with asthma varied between 0.14% and 19.1%. The use of inhaled corticosteroids (ICS) was associated with reduced risk for COVID‐19 (risk ratio [RR]: 0.60, 95% confidence interval [CI]: 0.40–0.90). Uncontrolled asthma, younger age, AND moderate–severe asthma were not significant risk factors for contracting COVID‐19. Children with asthma had an increased risk for hospitalization (RR: 1.62, 95% CI: 1.07–2.45) but were not more likely to require assisted ventilation (RR: 0.51, 95% CI: 0.14–1.90). The risk of COVID‐19 infection among children with CF was |
| doi_str_mv | 10.1002/ppul.26403 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2795357689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2795357689</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3163-61fb6133fd85dbd6bf2544bdb668fd4cac853d8e07edfe956ec870dfe07d5c213</originalsourceid><addsrcrecordid>eNp9kM1OGzEURi0EKoF2wwMgS2wQ0qT2eOyx2aGUFqRIRCp0O_LY18RofoI90yg7HqHP2Cep00AXLLq69-o7Orr6EDqhZEoJyT-vVmMzzUVB2B6aUKJURgol9tFElpxnQgp2iI5ifCIkZYp-QIesJLSggkyQu18C7sfB9G2aDs_uftx--f3yiyrsO2yWvrEBOrz2wzJdoe-8wc3YPWLrI-gIl_j7Jg7Q6iEFAX56WGPdWdzCoJNGd7rZRIgf0YHTTYRPr_MYPXy9vp_dZPO7b7ezq3lmGBUsE9TVgjLmrOS2tqJ2OS-K2tZCSGcLo43kzEogJVgHigswsiRpJaXlJqfsGJ3vvKvQP48Qh6r10UDT6A76MVZ5qTjjpZAqoWfv0Kd-DOnfREnKJFO52govdpQJfYwBXLUKvtVhU1FSbduvtu1Xf9tP8OmrcqxbsP_Qt7oTQHfA2jew-Y-qWiwe5jvpH1aEkak</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2813839291</pqid></control><display><type>article</type><title>The outcome of COVID‐19 in children with chronic lung disease: Systematic review and meta‐analyses</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sallih, Aimi Suhaili Mohd ; Wee, Mae Wae ; Zaki, Rafdzah A. ; Hng, Shih Ying ; Eg, Kah Peng ; Nathan, Anna M. ; Bruyne, Jessie A.</creator><creatorcontrib>Sallih, Aimi Suhaili Mohd ; Wee, Mae Wae ; Zaki, Rafdzah A. ; Hng, Shih Ying ; Eg, Kah Peng ; Nathan, Anna M. ; Bruyne, Jessie A.</creatorcontrib><description>Background
Few studies have examined the impact of Coronavirus disease 2019 (COVID‐19) infection on children with chronic lung disease (CLD).
Objective
To perform a systematic review and meta‐analysis to determine the prevalence, risk factors for contracting COVID‐19, and complications of COVID‐19, in children with CLD.
Methods
This systematic review was based on articles published between January 1, 2020 and July 25, 2022. Children under 18 years old, with any CLD and infected with COVID‐19 were included.
Results
Ten articles involving children with asthma and four involving children with cystic fibrosis (CF) were included in the analyses. The prevalence of COVID‐19 in children with asthma varied between 0.14% and 19.1%. The use of inhaled corticosteroids (ICS) was associated with reduced risk for COVID‐19 (risk ratio [RR]: 0.60, 95% confidence interval [CI]: 0.40–0.90). Uncontrolled asthma, younger age, AND moderate–severe asthma were not significant risk factors for contracting COVID‐19. Children with asthma had an increased risk for hospitalization (RR: 1.62, 95% CI: 1.07–2.45) but were not more likely to require assisted ventilation (RR: 0.51, 95% CI: 0.14–1.90). The risk of COVID‐19 infection among children with CF was <1%. Posttransplant and cystic fibrosis‐related diabetes mellitus (CFRDM) patients were at an increased risk for hospitalization and intensive care treatment.
Conclusion
Hospitalizations were higher in children with asthma with COVID‐19 infection. However, using ICS reduced the risk of COVID‐19 infection. As for CF, postlung transplantation and CFRDM were risk factors for severe disease.</description><identifier>ISSN: 8755-6863</identifier><identifier>EISSN: 1099-0496</identifier><identifier>DOI: 10.1002/ppul.26403</identifier><identifier>PMID: 37014160</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Administration, Inhalation ; Adolescent ; Adrenal Cortex Hormones - therapeutic use ; Anti-Asthmatic Agents - therapeutic use ; Asthma ; Asthma - drug therapy ; Child ; children ; chronic lung disease ; COVID-19 ; COVID-19 - complications ; COVID-19 - epidemiology ; Cystic fibrosis ; Cystic Fibrosis - complications ; Cystic Fibrosis - drug therapy ; Humans ; Infections ; Lung diseases ; meta‐analyses ; outcome ; Risk factors ; Systematic review</subject><ispartof>Pediatric pulmonology, 2023-06, Vol.58 (6), p.1784-1797</ispartof><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3163-61fb6133fd85dbd6bf2544bdb668fd4cac853d8e07edfe956ec870dfe07d5c213</cites><orcidid>0000-0002-6814-7418 ; 0000-0003-3618-5820 ; 0000-0003-2884-5198 ; 0000-0002-0730-8513 ; 0000-0003-4706-7467 ; 0000-0003-1418-283X ; 0000-0002-3388-6173</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fppul.26403$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fppul.26403$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37014160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sallih, Aimi Suhaili Mohd</creatorcontrib><creatorcontrib>Wee, Mae Wae</creatorcontrib><creatorcontrib>Zaki, Rafdzah A.</creatorcontrib><creatorcontrib>Hng, Shih Ying</creatorcontrib><creatorcontrib>Eg, Kah Peng</creatorcontrib><creatorcontrib>Nathan, Anna M.</creatorcontrib><creatorcontrib>Bruyne, Jessie A.</creatorcontrib><title>The outcome of COVID‐19 in children with chronic lung disease: Systematic review and meta‐analyses</title><title>Pediatric pulmonology</title><addtitle>Pediatr Pulmonol</addtitle><description>Background
Few studies have examined the impact of Coronavirus disease 2019 (COVID‐19) infection on children with chronic lung disease (CLD).
Objective
To perform a systematic review and meta‐analysis to determine the prevalence, risk factors for contracting COVID‐19, and complications of COVID‐19, in children with CLD.
Methods
This systematic review was based on articles published between January 1, 2020 and July 25, 2022. Children under 18 years old, with any CLD and infected with COVID‐19 were included.
Results
Ten articles involving children with asthma and four involving children with cystic fibrosis (CF) were included in the analyses. The prevalence of COVID‐19 in children with asthma varied between 0.14% and 19.1%. The use of inhaled corticosteroids (ICS) was associated with reduced risk for COVID‐19 (risk ratio [RR]: 0.60, 95% confidence interval [CI]: 0.40–0.90). Uncontrolled asthma, younger age, AND moderate–severe asthma were not significant risk factors for contracting COVID‐19. Children with asthma had an increased risk for hospitalization (RR: 1.62, 95% CI: 1.07–2.45) but were not more likely to require assisted ventilation (RR: 0.51, 95% CI: 0.14–1.90). The risk of COVID‐19 infection among children with CF was <1%. Posttransplant and cystic fibrosis‐related diabetes mellitus (CFRDM) patients were at an increased risk for hospitalization and intensive care treatment.
Conclusion
Hospitalizations were higher in children with asthma with COVID‐19 infection. However, using ICS reduced the risk of COVID‐19 infection. As for CF, postlung transplantation and CFRDM were risk factors for severe disease.</description><subject>Administration, Inhalation</subject><subject>Adolescent</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Child</subject><subject>children</subject><subject>chronic lung disease</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - complications</subject><subject>Cystic Fibrosis - drug therapy</subject><subject>Humans</subject><subject>Infections</subject><subject>Lung diseases</subject><subject>meta‐analyses</subject><subject>outcome</subject><subject>Risk factors</subject><subject>Systematic review</subject><issn>8755-6863</issn><issn>1099-0496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1OGzEURi0EKoF2wwMgS2wQ0qT2eOyx2aGUFqRIRCp0O_LY18RofoI90yg7HqHP2Cep00AXLLq69-o7Orr6EDqhZEoJyT-vVmMzzUVB2B6aUKJURgol9tFElpxnQgp2iI5ifCIkZYp-QIesJLSggkyQu18C7sfB9G2aDs_uftx--f3yiyrsO2yWvrEBOrz2wzJdoe-8wc3YPWLrI-gIl_j7Jg7Q6iEFAX56WGPdWdzCoJNGd7rZRIgf0YHTTYRPr_MYPXy9vp_dZPO7b7ezq3lmGBUsE9TVgjLmrOS2tqJ2OS-K2tZCSGcLo43kzEogJVgHigswsiRpJaXlJqfsGJ3vvKvQP48Qh6r10UDT6A76MVZ5qTjjpZAqoWfv0Kd-DOnfREnKJFO52govdpQJfYwBXLUKvtVhU1FSbduvtu1Xf9tP8OmrcqxbsP_Qt7oTQHfA2jew-Y-qWiwe5jvpH1aEkak</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Sallih, Aimi Suhaili Mohd</creator><creator>Wee, Mae Wae</creator><creator>Zaki, Rafdzah A.</creator><creator>Hng, Shih Ying</creator><creator>Eg, Kah Peng</creator><creator>Nathan, Anna M.</creator><creator>Bruyne, Jessie A.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6814-7418</orcidid><orcidid>https://orcid.org/0000-0003-3618-5820</orcidid><orcidid>https://orcid.org/0000-0003-2884-5198</orcidid><orcidid>https://orcid.org/0000-0002-0730-8513</orcidid><orcidid>https://orcid.org/0000-0003-4706-7467</orcidid><orcidid>https://orcid.org/0000-0003-1418-283X</orcidid><orcidid>https://orcid.org/0000-0002-3388-6173</orcidid></search><sort><creationdate>202306</creationdate><title>The outcome of COVID‐19 in children with chronic lung disease: Systematic review and meta‐analyses</title><author>Sallih, Aimi Suhaili Mohd ; Wee, Mae Wae ; Zaki, Rafdzah A. ; Hng, Shih Ying ; Eg, Kah Peng ; Nathan, Anna M. ; Bruyne, Jessie A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3163-61fb6133fd85dbd6bf2544bdb668fd4cac853d8e07edfe956ec870dfe07d5c213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Administration, Inhalation</topic><topic>Adolescent</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Child</topic><topic>children</topic><topic>chronic lung disease</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - complications</topic><topic>Cystic Fibrosis - drug therapy</topic><topic>Humans</topic><topic>Infections</topic><topic>Lung diseases</topic><topic>meta‐analyses</topic><topic>outcome</topic><topic>Risk factors</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sallih, Aimi Suhaili Mohd</creatorcontrib><creatorcontrib>Wee, Mae Wae</creatorcontrib><creatorcontrib>Zaki, Rafdzah A.</creatorcontrib><creatorcontrib>Hng, Shih Ying</creatorcontrib><creatorcontrib>Eg, Kah Peng</creatorcontrib><creatorcontrib>Nathan, Anna M.</creatorcontrib><creatorcontrib>Bruyne, Jessie A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric pulmonology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sallih, Aimi Suhaili Mohd</au><au>Wee, Mae Wae</au><au>Zaki, Rafdzah A.</au><au>Hng, Shih Ying</au><au>Eg, Kah Peng</au><au>Nathan, Anna M.</au><au>Bruyne, Jessie A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The outcome of COVID‐19 in children with chronic lung disease: Systematic review and meta‐analyses</atitle><jtitle>Pediatric pulmonology</jtitle><addtitle>Pediatr Pulmonol</addtitle><date>2023-06</date><risdate>2023</risdate><volume>58</volume><issue>6</issue><spage>1784</spage><epage>1797</epage><pages>1784-1797</pages><issn>8755-6863</issn><eissn>1099-0496</eissn><abstract>Background
Few studies have examined the impact of Coronavirus disease 2019 (COVID‐19) infection on children with chronic lung disease (CLD).
Objective
To perform a systematic review and meta‐analysis to determine the prevalence, risk factors for contracting COVID‐19, and complications of COVID‐19, in children with CLD.
Methods
This systematic review was based on articles published between January 1, 2020 and July 25, 2022. Children under 18 years old, with any CLD and infected with COVID‐19 were included.
Results
Ten articles involving children with asthma and four involving children with cystic fibrosis (CF) were included in the analyses. The prevalence of COVID‐19 in children with asthma varied between 0.14% and 19.1%. The use of inhaled corticosteroids (ICS) was associated with reduced risk for COVID‐19 (risk ratio [RR]: 0.60, 95% confidence interval [CI]: 0.40–0.90). Uncontrolled asthma, younger age, AND moderate–severe asthma were not significant risk factors for contracting COVID‐19. Children with asthma had an increased risk for hospitalization (RR: 1.62, 95% CI: 1.07–2.45) but were not more likely to require assisted ventilation (RR: 0.51, 95% CI: 0.14–1.90). The risk of COVID‐19 infection among children with CF was <1%. Posttransplant and cystic fibrosis‐related diabetes mellitus (CFRDM) patients were at an increased risk for hospitalization and intensive care treatment.
Conclusion
Hospitalizations were higher in children with asthma with COVID‐19 infection. However, using ICS reduced the risk of COVID‐19 infection. As for CF, postlung transplantation and CFRDM were risk factors for severe disease.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37014160</pmid><doi>10.1002/ppul.26403</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-6814-7418</orcidid><orcidid>https://orcid.org/0000-0003-3618-5820</orcidid><orcidid>https://orcid.org/0000-0003-2884-5198</orcidid><orcidid>https://orcid.org/0000-0002-0730-8513</orcidid><orcidid>https://orcid.org/0000-0003-4706-7467</orcidid><orcidid>https://orcid.org/0000-0003-1418-283X</orcidid><orcidid>https://orcid.org/0000-0002-3388-6173</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8755-6863 |
| ispartof | Pediatric pulmonology, 2023-06, Vol.58 (6), p.1784-1797 |
| issn | 8755-6863 1099-0496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2795357689 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Inhalation Adolescent Adrenal Cortex Hormones - therapeutic use Anti-Asthmatic Agents - therapeutic use Asthma Asthma - drug therapy Child children chronic lung disease COVID-19 COVID-19 - complications COVID-19 - epidemiology Cystic fibrosis Cystic Fibrosis - complications Cystic Fibrosis - drug therapy Humans Infections Lung diseases meta‐analyses outcome Risk factors Systematic review |
| title | The outcome of COVID‐19 in children with chronic lung disease: Systematic review and meta‐analyses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T09%3A49%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20outcome%20of%20COVID%E2%80%9019%20in%20children%20with%20chronic%20lung%20disease:%20Systematic%20review%20and%20meta%E2%80%90analyses&rft.jtitle=Pediatric%20pulmonology&rft.au=Sallih,%20Aimi%20Suhaili%20Mohd&rft.date=2023-06&rft.volume=58&rft.issue=6&rft.spage=1784&rft.epage=1797&rft.pages=1784-1797&rft.issn=8755-6863&rft.eissn=1099-0496&rft_id=info:doi/10.1002/ppul.26403&rft_dat=%3Cproquest_cross%3E2795357689%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2813839291&rft_id=info:pmid/37014160&rfr_iscdi=true |